23:06 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Gram-negative bacterial infection In vitro and cell culture studies identified triazolopyrimidinone- and azabenzimidazole-based bacterial coaD inhibitors that could help treat Gram-negative bacterial infection. Fragment-based screening, chemical synthesis and in vitro binding assays yielded a triazolopyrimidinone...
08:00 , Dec 7, 2009 |  BioCentury  |  Strategy

Meeting the Biota Quota

Biota Holdings Ltd.'s acquisition of MaxThera Inc. and Prolysis Ltd. fills some holes in its pipeline, which should help it achieve its long-term goal of having two or three out-licensed, royalty-generating compounds on the market...